Brief: Anthera announces positive DSMB review in phase 3 solution study of Sollpura
16/08/2016 13:47
Aug 16 (Reuters) - Anthera Pharmaceuticals Inc ANTH.O
* Announces positive DSMB review in phase 3 solution study
of Sollpura
* DSMB had "no concerns regarding safety of data to date,
and voted that study continue without modification to protocol
or charter."
Source text for Eikon: ID:nGNXMZJDEa
Further company coverage: ANTH.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Anthera Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-Micron, Darden, Kroger, American Outdoor
Brief: Anthera Pharma's Board Approves Personnel Reorganization Plan
U.S. STOCKS ON THE MOVE-Anthera, Oclaro, Intel, Broadcom, Netflix, BlueLinx, Micron
U.S. STOCKS ON THE MOVE-Anthera, Oclaro, Intel, Broadcom, BlueLinx, Orexigen, Micron
U.S. STOCKS ON THE MOVE-Anthera, Oclaro, Intel, Broadcom, Orexigen, Goldman